Umoja Biopharma Launches with $53M Series A Financing to Develop Fully Integrated, Scalable, In Vivo Immunotherapy Platform
Umoja's platform addresses key limitations of existing engineered immunotherapies
Company backed by prominent life science investors MPM Capital, DCVC Bio and Qiming Venture Partners USA and led by an experienced team of scientist/entrepreneurs
SEATT... Biopharmaceuticals, Oncology, Venture Capital Umoja Biopharma, immunotherapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news